Autopsy report · NCT00760916

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study stopped prior to subject enrollment.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 3
Sponsor: United Therapeutics
Sponsor type: Industry
Conditions: Pulmonary Hypertension
Interventions: UT-15C 1 mg; UT-15C 0.25 mg; UT-15C 5 mg; Placebo
Participants: 0
Sites: 31
Countries: Australia, Mexico, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.